Assenagon Asset Management’s Ovid Therapeutics OVID Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$43.7K Hold
17,544
– – ﹤0.01% 1094
2026
Q2
$47.2K Sell
17,544
-210,198
-92% -$542K ﹤0.01% 1157
2026
Q1
$506K Sell
227,742
-390,277
-63% -$698K ﹤0.01% 1004
2025
Q4
$1.01M Sell
618,019
-306,557
-33% -$472K ﹤0.01% 943
2025
Q3
$1.2M Buy
924,576
+488,956
+112% +$424K ﹤0.01% 898
2025
Q2
$144K Sell
435,620
-125,210
-22% -$37.7K ﹤0.01% 1126
2025
Q1
$175K Buy
560,830
+490,716
+700% +$302K ﹤0.01% 1117
2024
Q4
$65.5K Sell
70,114
-16,175
-19% -$18.1K ﹤0.01% 1298
2024
Q3
$102K Buy
+86,289
New +$90.2K ﹤0.01% 1347
2024
Q2
– Sell
-114,265
Closed -$349K – 1474
2024
Q1
$349K Buy
114,265
+35,786
+46% +$120K ﹤0.01% 1265
2023
Q4
$253K Buy
+78,479
New +$268K ﹤0.01% 1346
2022
Q3
– Sell
-26,362
Closed -$57K – 1497
2022
Q2
$57K Buy
+26,362
New +$63.7K ﹤0.01% 1423
2021
Q4
– Sell
-334,589
Closed -$1.12M – 1524
2021
Q3
$1.12M Buy
+334,589
New +$1.22M ﹤0.01% 874
2020
Q3
– Sell
-510,302
Closed -$3.76M – 1299
2020
Q2
$3.76M Buy
510,302
+390,242
+325% +$1.83M 0.02% 404
2020
Q1
$358K Buy
120,060
+54,154
+82% +$182K ﹤0.01% 692
2019
Q4
$274K Buy
+65,906
New +$208K ﹤0.01% 708

Other funds holding OVID

Assenagon Asset Management's OVID Position: Q3 2026 in Review

Assenagon Asset Management held its Ovid Therapeutics (OVID) position steady in Q3 2026 at 17,544 shares worth $43.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1094.

Assenagon Asset Management first reported a position in OVID in Q4 2019 and has held it in 16 quarters since. The position peaked at $3.76M in Q2 2020. 129 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

  • Assenagon Asset Management held 17,544 shares of Ovid Therapeutics worth $43.7K as of Q3 2026.
  • Assenagon Asset Management left its Ovid Therapeutics share count unchanged in Q3 2026.
  • Ovid Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q3 2026, its #1094 holding.
  • Assenagon Asset Management first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 16 quarters since.
  • Assenagon Asset Management's Ovid Therapeutics position peaked at $3.76M in Q2 2020.
  • 129 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on Assenagon Asset Management's 13F filing for Q3 2026, filed 15 Oct 2026.